Literature DB >> 18182499

Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids.

Robert-Jan Sanders1, Rob Ofman, Georges Dacremont, Ronald J A Wanders, Stephan Kemp.   

Abstract

Very-long-chain fatty acids (VLCFAs) have long been known to be degraded exclusively in peroxisomes via beta-oxidation. A defect in peroxisomal beta-oxidation results in elevated levels of VLCFAs and is associated with the most frequent inherited disorder of the central nervous system white matter, X-linked adrenoleukodystrophy. Recently, we demonstrated that VLCFAs can also undergo omega-oxidation, which may provide an alternative route for the breakdown of VLCFAs. The omega-oxidation of VLCFA is initiated by CYP4F2 and CYP4F3B, which produce omega-hydroxy-VLCFAs. In this article, we characterized the enzymes involved in the formation of very-long-chain dicarboxylic acids from omega-hydroxy-VLCFAs. We demonstrate that very-long-chain dicarboxylic acids are produced via two independent pathways. The first is mediated by an as yet unidentified, microsomal NAD(+)-dependent alcohol dehydrogenase and fatty aldehyde dehydrogenase, which is encoded by the ALDH3A2 gene and is deficient in patients with Sjögren-Larsson syndrome. The second pathway involves the NADPH-dependent hydroxylation of omega-hydroxy-VLCFAs by CYP4F2, CYP4F3B, or CYP4F3A. Enzyme kinetic studies show that oxidation of omega-hydroxy-VLCFAs occurs predominantly via the NAD(+)-dependent route. Overall, our data demonstrate that in humans all enzymes are present for the complete conversion of VLCFAs to their corresponding very-long-chain dicarboxylic acids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18182499     DOI: 10.1096/fj.07-099150

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

1.  Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients.

Authors:  Paula B M Luís; Jos P Ruiter; Lodewijk IJlst; Luísa Diogo; Paula Garcia; Isabel Tavares de Almeida; Marinus Duran; Ronald J Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

Review 2.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

Review 3.  Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.

Authors:  Paul P Van Veldhoven
Journal:  J Lipid Res       Date:  2010-06-17       Impact factor: 5.922

4.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

Review 5.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

6.  Essential role of the cytochrome P450 CYP4F22 in the production of acylceramide, the key lipid for skin permeability barrier formation.

Authors:  Yusuke Ohno; Shota Nakamichi; Aya Ohkuni; Nozomi Kamiyama; Ayano Naoe; Hisashi Tsujimura; Urara Yokose; Kazumitsu Sugiura; Junko Ishikawa; Masashi Akiyama; Akio Kihara
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

7.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

Review 8.  Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function.

Authors:  William B Rizzo
Journal:  Biochim Biophys Acta       Date:  2013-09-12

9.  Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.

Authors:  Katheryne Z Edson; Bhagwat Prasad; Jashvant D Unadkat; Yoshitomo Suhara; Toshio Okano; F Peter Guengerich; Allan E Rettie
Journal:  Biochemistry       Date:  2013-11-07       Impact factor: 3.162

10.  Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion.

Authors:  William B Rizzo; Dana S'Aulis; M Anitia Jennings; Debra A Crumrine; Mary L Williams; Peter M Elias
Journal:  Arch Dermatol Res       Date:  2010-01-05       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.